Core Insights - The innovative drug HRS-1893 has achieved a significant breakthrough with a licensing agreement between Heng Rui Medicine and Braveheart Bio, with a potential total transaction value of nearly 8 billion RMB [1][5] - The collaboration highlights the international recognition of China's innovative drug research and the focus on Southeast University's organ-on-a-chip technology [1][5] Group 1: Drug Development and Mechanism - HRS-1893 is designed to treat obstructive hypertrophic cardiomyopathy and functions as a selective inhibitor of cardiac myosin [3] - The drug's development involved collaboration with Professor Gu Zhongze's team at Southeast University, utilizing organ-on-a-chip technology for cell activity screening [3][7] Group 2: Clinical Trials and Licensing Agreement - HRS-1893 received approval for clinical trials in May 2023, marking it as the first new drug in China to use organ-on-a-chip data for such approval [5] - Braveheart Bio will have exclusive rights to develop, produce, and commercialize HRS-1893 globally, excluding certain regions in China, with Heng Rui Medicine set to receive an upfront payment of $7.5 million and potential milestone payments totaling up to $1.013 billion [5][8] Group 3: Technological Advancements and Future Plans - The organ-on-a-chip team at Southeast University has made significant advancements in key technologies over the past decade, achieving breakthroughs in high-precision 3D printing and functional biomaterials [7] - Future plans include further technological innovation and collaboration with more pharmaceutical companies to create new pathways for drug development and precision medicine [8]

以"芯片"为地基，用细胞做"砖瓦"，流动的"血管"、跳动的"心脏"、呼吸的"肺"……一系列微型器官在 方寸之地生长并运行。这不是科幻片中的场景，而是即将改变你我生活的器官芯片。 通常而言，我们谈到的芯片指硅基芯片，是以半导体硅为基底制造的微型电子电路，可以高效处理二进 制信息，实现复杂的计算任务。 在医学研究领域有一种新型"芯片"，电子线路被流体流动的通道取代，由干细胞、生物材料、纳米加工 等技术交叉集成。研究人员借鉴计算机芯片的制造方法，注入某一人体目标器官细胞，利用不同的通道 输入氧气、培养液等，营造出接近体内的生长环境，搭建出一个个迷你器官。 与电子芯片的物理形态和制作工艺类似，器官芯片通常也是在微小透明薄片上"雕刻"出通道和腔室，研 究人员利用微流控技术在微管道里精准操控微小流体；与电子芯片的设计理念和集成度类似，器官芯片 也能在方寸之间集成多种复杂器官功能；与电子芯片的标准化、模块化、高通量特性类似，不同芯片可 模拟不同器官，甚至可以像多个电子芯片模块化组成"人体芯片"，进行药物高通量研发测试。因此，器 官芯片可以说是对芯片概念的延伸。 2009年前后，第一个功能齐全的器官芯片——"肺芯片"在美国问 ...

Core Viewpoint - The development of organ-on-a-chip technology by Wuhan First Hospital significantly reduces the drug research and development cycle and experimental costs while improving the accuracy of experimental data [4][5][10]. Group 1: Organ-on-a-Chip Technology - The organ-on-a-chip technology can simulate various human organs, including blood vessels, skin, liver, intestines, and kidneys, allowing for preclinical research that replaces traditional cell models and animal testing [2][5]. - The multi-organ chip integrates multiple organ models and can simulate complex physiological and pathological processes, such as blood circulation, thereby enhancing the efficiency of drug development [5][9]. - The single-organ chip, such as the skin chip, can grow skin tissue with a layered structure from a small sample, providing a more accurate model for testing cosmetic products and drug efficacy [5][8]. Group 2: Applications in Drug Development - The organ-on-a-chip technology allows for real-time observation of cancer cell behavior and drug interactions, facilitating personalized treatment approaches, especially for cancer patients [9]. - The technology has been successfully used to create disease models for over 20 conditions, including atopic dermatitis and drug-induced liver injury, enhancing the understanding of disease mechanisms [9]. - The introduction of skin chips has improved the efficiency of testing cosmetic products, allowing for direct observation of collagen fiber growth and pigment deposition without relying on animal models [10].